The Concurrent Use of Rhus verniciflua Stokes as Complementary Therapy with Second or More Line Regimens on Advanced Non-small-cell Lung Cancer: Case Series
´ëÇÑÇÑÀÇÇÐȸÁö 2009³â 30±Ç 6È£ p.112 ~ p.117
ÀÌ»óÇå(Lee Sang-Hun) - °æÈñ´ëÇб³ ÇÑÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
±è°æ¼®(Kim Kyung-Suk) - °æÈñ´ëÇб³ ÇÑÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
ÃÖ¿øö(Choi Won-Chul) - °æÈñ´ëÇб³ ÇÑÀÇ°ú´ëÇÐ ÀÓ»óÁ¾¾çÇаú
À±¼º¿ì(Yoon Seong-Woo) - °æÈñ´ëÇб³ ÇÑÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
Abstract
Objective: Rhus verniciflua Stokes (RVS) has anticancer effect confirmed by preclinical studies and historical records. We thus tried to evaluate retrospectively the effect of RVS as a complementary medicine for patients with advanced non-small-cell lung cancer (NSCLC) showing refractory to conventional chemotherapy.
Patients and Methods: From June 1, 2006 to June 30, 2007, patients with advanced NSCLC who received both the standardized RVS extract and a standard course of second or more line therapy such as pemetrexed (Alimta¢ç), erlotinib (Tarceva¢ç), and gefitinib (Iressa¢ç) were checked. A total of 13 patients were eligible for the final analysis after fulfilling inclusion/exclusion criteria. Time to progression (TTP) of these patients treated with the standardized RVS extract was checked in the aftercare period.
Results: Patients received RVS treatment for a median period of 296 (range 84-698) days. The median TTP was
220.5 (range 36-489) days, and three patients (23.1%) had TTP values of 15 more months. No significant side effects from RVS treatment have been observed.
Conclusion: The standardized RVS extract might have synergetic effects by assisting apoptosis in advanced NSCLC with concurrent standard therapy agents, since it prolonged TTP without significant adverse effects. This study
suggests that the standardized RVS extract is beneficial to patients with chemotherapy-refractory NSCLC. Further clinical trials and preclinical studies are necessary to determine the efficacy and safety of the standardized RVS extract in NSCLC.
Å°¿öµå
Rhus verniciflua Stokes, flavonoids, antineoplastic agents, non-small cell lung carcinoma
KMID :
0363620090300060112
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
À¯È¿¼º°á°ú(Recomendation)
RVS extract is beneficial to patients with chemotherapy-refractory NSCLC. No significant side effects from RVS treatment have been observed. The standardized RVS extract might have synergetic effects by assisting apoptosis in advanced NSCLC with concurrent standard therapy agents